Loading ......
Filter By Product Search for
BMPR2
BMPR2 Full Name
bone morphogenetic protein receptor, type II (serine/threonine kinase)
BMPR2 Introduction
BMPR2 occupies a special place in the TGF-beta receptor family as the type II serine/threonine kinase that initiates canonical BMP signalling. The gene maps to 2q33.1-q33.2 and encodes a receptor with a short extracellular ligand-binding domain, a single transmembrane helix and an intracellular kinase domain that is constitutively active, so that the receptor is poised to phosphorylate type I partners as soon as ligand is bound. It is expressed in virtually all tissues, with particularly high levels in vascular endothelium and in pulmonary artery smooth muscle, and its transcript is subject to alternative splicing that generates a short isoform with a truncated kinase domain.
Figure 1. Structural consequences of BMPR2 kinase domain mutations.
Receptor Complex Assembly and Smad Activation
Ligand binding promotes BMPR2 to recruit and transphosphorylate one of several type I receptors, principally ALK1, ALK2, ALK3 or ALK6, and the choice of partner determines downstream output: ALK1 in endothelial cells engages Smad1/5/8, whereas ALK3 acts in mesenchymal cells. Beyond Smads, BMPR2 signals through TAK1 and p38, through PI3K-AKT and through the LIM kinase cascade that controls actin dynamics. The receptor is also subject to regulated endocytosis; internalisation into caveolae favours Smad signalling while clathrin-mediated uptake favours degradation, and this spatial control of BMPR2 is critical for shaping the duration of the signal.
Pulmonary Arterial Hypertension and Vascular Remodelling
Heterozygous BMPR2 mutations are the commonest monogenic cause of heritable pulmonary arterial hypertension, accounting for roughly three-quarters of familial cases and a fifth of sporadic disease, although penetrance is only about 20 percent, implying modifier genes and environmental triggers. Haploinsufficiency predisposes endothelial cells to apoptosis and selects for apoptosis-resistant, proliferative clones that obliterate small pulmonary arterioles. Reduced BMPR2 signalling also shifts the balance towards TGF-beta/ALK5 activity, promoting endothelial-to-mesenchymal transition and matrix deposition. Agents that restore BMP signalling, including sotatercept, a ligand trap for activin and growth differentiation factors, have validated this pathway therapeutically.
Alternate Names for BMPR2
BMPR2; bone morphogenetic protein receptor, type II (serine/threonine kinase); PPH1, primary pulmonary hypertension 1; bone morphogenetic protein receptor type-2; BMPR II; BMPR3; BRK 3; T ALK; BMPR-2; BMP type-2 receptor
Loading ......